Tofacitinib controlled release (Triastek)

枸橼酸托法替布延迟缓释片（南京三迭纪）

Report date: 2026/05/12 20:00:17

Base Information

Drug NameTofacitinib controlled release (Triastek)
Drug Alias NameT-21T21T-19
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK3 inhibitorsTyrosine-protein kinase JAK2 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK3Tyrosine-protein kinase JAK2
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Triastek Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A